PhaseBio Pharmaceuticals Inc: insider trades · United States · SEC (Form 4)

About PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company that was listed on the NASDAQ in the United States (United States). The company was incorporated as a Delaware corporation on January 10, 2002, and built its identity around cardiovascular drug development rather than a broad commercial pharma franchise. Its historical operational footprint was centered in Malvern, Pennsylvania, and its business model relied on clinical development, regulatory execution, and selective partnering rather than a large in-house sales organization. ([phasebio.com](https://phasebio.com/investors-sub/static-files/586a9374-207b-4eae-ad1a-16d4063ba2ec.pdf?utm_source=openai)) From an equity-research perspective, PhaseBio was best understood as a highly focused clinical-stage biotech. Its lead asset was bentracimab (PB2452), a first-in-class reversal agent designed to rapidly restore platelet function in patients treated with ticagrelor who experience major bleeding or require urgent surgery. The pipeline also included pemziviptadil (PB1046), a program aimed at pulmonary arterial hypertension, and PB6440, an oral aldosterone synthase inhibitor intended for resistant hypertension and potentially other cardio-renal indications. This narrow therapeutic concentration gave the company a clear scientific narrative, but it also made the investment case heavily dependent on a small number of assets and milestones. ([phasebio.com](https://phasebio.com/pipeline/?utm_source=openai)) In competitive terms, PhaseBio operated in one of the most demanding areas of biotechnology: cardiovascular and acute-care medicine, where differentiation depends on clinical efficacy, safety, manufacturability, and regulatory credibility. Bentracimab was the company’s core value driver, with a proposition that could have been clinically meaningful if supported by successful data and approval. The company also pursued external collaboration as part of its strategy, including a licensing agreement with Alfasigma for bentracimab commercialization in Europe and other markets, showing an intent to create geographic optionality without building a global commercial platform from scratch. ([phasebio.com](https://phasebio.com/investors-sub/news-releases/news-release-details/phasebio-announces-successful-pre-bla-meeting-us-fda-bentracimab/?utm_source=openai)) Geographically, PhaseBio’s operations were primarily U.S.-centric, reflecting its clinical, regulatory, and corporate base, but parts of its development and partnering strategy extended into Europe and China. That international footprint was still limited and program-specific rather than a sign of a mature multinational business. ([phasebio.com](https://phasebio.com/investors-sub/news-releases/news-release-details/phasebio-announces-successful-pre-bla-meeting-us-fda-bentracimab/?utm_source=openai)) A key recent development for investors is that PhaseBio stopped further development of pemziviptadil and refocused resources on bentracimab and PB6440, before entering a severe financial and restructuring phase. The company filed a voluntary Chapter 11 petition in October 2022, and more recent SEC-related materials reference its delisting from NASDAQ following that process. As a result, PhaseBio should be viewed less as an operating growth story and more as a distressed biotech case where value is tied to the underlying asset base, intellectual property, and any restructuring or transaction outcome. ([phasebio.com](https://phasebio.com/investors-sub/news-releases/news-release-details/phasebio-pharmaceuticals-reports-first-quarter-2022-financial/?utm_source=openai))